Viatris SWOT and PESTLE Analysis
COMPANY PROFILE -Viatris
Business Sector :Pharmaceuticals
Operating Geography :United States, North America, Global
About Viatris :
Viatris is a global pharmaceutical company formed in 2020 through the merger of Mylan and Upjohn, a division of Pfizer. The company is headquartered in Pittsburgh, Pennsylvania, and has a presence in over 165 countries around the world. Viatris is focused on developing and manufacturing generic and branded pharmaceuticals, as well as over-the-counter medications, biosimilars, and complex generics. The company's portfolio includes treatments for a variety of medical conditions, including cardiovascular disease, diabetes, and respiratory illness. In addition to its pharmaceutical operations, Viatris is also committed to expanding access to healthcare and promoting sustainability. The company has partnerships with a variety of organizations to support healthcare initiatives and improve access to medications in underserved communities. Viatris has been included in the top 10% of a list of 800 global employers for 2022. As of early 2023, Viatris employed over 37,000 people.
The USP of Viatris lies in it being Viatris’ one of the leading global healthcare companies. mission statement reads, “We act courageously and are uniquely positioned to be a source of stability in a world of evolving healthcare needs. Viatris empowers people worldwide to live healthier at every stage of life.”
Viatris Revenue :
US$ 16,218 million - FY ending 31st December 2022 (y-o-y decline 9%)
US$ 17,886 million - FY ending 31st December 2021
Competitive Analysis of Viatris
Strengths | Weaknesses |
1. A global healthcare company catering to patients in more than 165 countries with 1400+ approved molecules. 2. Strong and reliable supply chain. 3. Viatris is the culmination of Mylan’s strategic efforts and Upjohn’s strong portfolio efforts. 4. Continued and remarkable brand performance across all segments. 5. Solid growth in Europe along with better revenue generation as compared to that from North America | 1. Viatris employees involved in insider trading and securities fraud. |
Opportunities | Threats |
1. Viatris acquisitions last year are eyeing on becoming the global leader in eye care. 2. Viatris is aiming towards growing beyond generics only player. 3. Broadening the drug portfolio of Viatris across various geographies organically and through business development. 4. Viatris is the leading drugmaker towards attaining production autonomy overseas. | 1. Viatris’s competitors are likely to raise drug prices in response to IRA. 2. Legal battles for securing patents from competitors leads to delays in product launch. 3. Competitor firm Thea Pharma gets FDA nod to launch a competitive product in the eye care segment. |
Complete Report
USD 27
- Debit/Credit card
- PayPal
Detailed SWOT Analysis of Viatris
Strength
1. A global healthcare company catering to patients in more than 165 countries with 1400+ approved molecules: Viatris was established in November 2020, built on the foundation of its legacy entities Mylan and Upjohn. Viatris boasts of its deep market expertise and unparalleled global reach. Built on the legacies of its entities, Viatris has a deep market expertise to its leverage which ensures its growth. At present Viatris customizes to offer its service to each market segment that it caters to separately. With Developed markets contributing to 60% of the total revenue, Viatris caters to more than 165 countries globally with its world class infrastructure through multiple channels. The company’s portfolio boasts about approved 1400+ molecules and 30,000 SKU’s, globally recognized iconic brands, Broad range of medicines, spanning both non-communicable and infectious diseases, 10 therapeutic areas. Global franchise with 7 biosimilar molecules is already on the market. All this is delivered by unique global platform which is flexible enough to meet the customers need driven by the ability to supply markets of varying sizes.
2. Strong and reliable manufacturing and supply chain: The reason behind the strong and exponential growth of Viatris has been its resilient supply chain network. Pharmaceutical industry is one such which suffers the most in times of emergency as we saw during COVID-19 time. Availability of life saving drugs in such crucial times is the game changer. With near about 50 manufacturing sites which are at proximity to key markets, Viatris has been the talk globally. Combining these manufacturing sites with more five continents globally, Viatris while partnering up with third parties on manufacturing, development, supply and logistics, offer a worldwide, strategically located network of robust size and scope. Ensuring strong quality culture, Viatris’s manufacturing and supply network is customer oriented ensuring supply continuity. With experienced leadership teams, conducting more than 100 health authority inspections annually and continued focus on quality and compliance, safety and sustainability is ensured. With Rapid Response Advanced Planning system, Viatris ensures that all stakeholders are well interconnected globally. Incorporating such measures helps the company to plan out stock in advance to deal better with problems relating to under or overstocking.
The remaining section under "Strength" is available only in the 'Complete Report' on purchase.
Weakness
This section is available only in the 'Complete Report' on purchase.
Opportunity
This section is available only in the 'Complete Report' on purchase.
Threat
This section is available only in the 'Complete Report' on purchase.
Major Competitors :
- Merck & Co Inc.
- GSK plc
- Teva Pharmaceutical Industries Ltd
- AstraZeneca
- Sandoz Inc
- Sanofi
- Amgen Inc.
- Astellas Pharma Inc.
- Moderna, Inc.
- BioNTech SE
- Novo Nordisk
- Boehringer Ingelheim
- Pfizer Inc.
Major Brands :
- Lipitor
- Norvasc
- Nitrostat
- Creon
- Celebrex
- Lyrica
- Viagra
- Dilantin
- Effexor
- Zoloft
- EpiPen
Complete Report
USD 27
- Debit/Credit card
- PayPal
TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
You may also be interested in other analyses of Viatris:
-
Viatris Porter's Five Forces Analysis -
Viatris VRIO Analysis -
Viatris Value Chain Analysis -
Viatris Covid-19 Impact Analysis -
Viatris BCG Analysis -
Viatris Segmentation, Targeting and Positioning (STP) Analysis -
Viatris Ansoff Matrix Analysis
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Check Out Analysis of Other Relevant Companies
References used in Viatris SWOT & PESTLE Analysis Report
1. Annual Report - https://investor.viatris.com/static-files/21535155-01c3-44e1-b8d9-0b1ca83616c0
2. Viatris executive charged in insider trading scheme that allegedly netted $7.2 million - https://www.fiercepharma.com/pharma/viatris-executive-charged-insider-trading-scheme-netted-72-million
3. Exclusive: Drugmakers to raise prices on at least 350 drugs in U.S. in January - https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-raise-prices-least-350-drugs-us-january-2022-12-30/
4. Pfizer-Mylan combo Viatris to slash up to 9,000 jobs, shutter manufacturing plants in global cost-cutting drive - https://www.fiercepharma.com/manufacturing/viatris-could-cut-up-to-9-000-global-manufacturing-jobs-as-it-plows-ahead-1b-saving
The detailed complete set of references are available on request in the 'Complete report' on purchase.
How to Reference This Page?
You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.
Viatris SWOT and PESTLE Analysis - SWOT & PESTLE.COM
SWOT & PESTLE.com (2024). Viatris SWOT and PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/viatris/ [Accessed 19 Sep, 2024].
In-text: (SWOT & PESTLE.com, 2024)
Copyrights and Disclaimer
Viatris SWOT and PESTLE analysis has been conducted by Rashim Verma and reviewed by senior analysts from Barakaat Consulting.
Copyright of Viatris SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.